Euroapi Company Header Euroapi Company Header

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"SIFI","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SIFI Completes Enrollment of the Phase III Study of Polihexanide 0.08% for the Treatment of Acanthamoeba Keratitis","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"ITALY","productType":"Small molecule","productStatus":"Approved","date":"November 2020","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical"},{"orgOrder":0,"company":"SIFI","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SIFI Initiates Patient Enrollment in Phase II Trial evaluating Pro-Ocular in Dry Eye Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"ITALY","productType":"Small molecule","productStatus":"Approved","date":"April 2021","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II\/ Phase III"},{"orgOrder":0,"company":"SIFI","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sifi Receives Favorable Feedback From the US FDA on Akantior\u00ae for the Treatment of Acanthamoeba Keratitis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"ITALY","productType":"Small molecule","productStatus":"Approved","date":"May 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"SIFI","sponsor":"Durbin","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sifi Announces EMA Validation Of Its Marketing Authorisation Application For Akantior For The Treatment Of Acanthamoeba Keratitis And The Opening Of An Early Access Program","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"ITALY","productType":"Small molecule","productStatus":"Approved","date":"June 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"SIFI","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SIFI Reports Detailed Positive Results and New Data from the Completed Phase 3 Trial of AKANTIOR\u00ae in Patients with Acanthamoeba Keratitis presented at the American Academy of Ophthalmology Annual Meeting in Chicago","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"ITALY","productType":"Small molecule","productStatus":"Approved","date":"October 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"SIFI","sponsor":"Alimera Sciences","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alimera Announces Approval and Pricing Granted for ILUVIEN for Uveitis in Italy","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase IV","country":"ITALY","productType":"Small molecule","productStatus":"Approved","date":"July 2022","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase IV"},{"orgOrder":0,"company":"SIFI","sponsor":"Avanzanite Bioscience","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sifi Announces License Agreement with Avanzanite Bioscience for Akantior\u00ae","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"ITALY","productType":"Small molecule","productStatus":"Approved","date":"January 2023","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"SIFI","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Avanzanite\u2019s AKANTIOR\u00ae Gets Positive CHMP Opinion and Expands into 26 European Countries","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"ITALY","productType":"Small molecule","productStatus":"Approved","date":"June 2024","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"SIFI","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SIFI Receives Positive CHMP Opinion for AKANTIOR in Acanthamoeba Keratitis","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"ITALY","productType":"Small molecule","productStatus":"Approved","date":"May 2024","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"}]

    Find Clinical Drug Pipeline Developments & Deals by SIFI

    Menu

    SIFI

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    DOSSIERs // Finished Dosage Forms

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              SIFI

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Italy
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Avanzanite’s AKANTIOR® Gets Positive CHMP Opinion and Expands into 26 European Countries

              Details:

              Akantior (polihexanide) is an investigational anti-amoebic polymer that recieved positive opinion from European Medicines Agency for the treament of acanthamoeba keratitis.

              Lead Product(s): Polyhexanide

              Therapeutic Area: Infections and Infectious Diseases Product Name: Akantior

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable June 03, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              SIFI

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Italy
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              SIFI Receives Positive CHMP Opinion for AKANTIOR in Acanthamoeba Keratitis

              Details:

              Akantior® (polihexanide) is an investigational anti-amoebic polymer that recieved positive opinion from European Medicines Agency for the treament of acanthamoeba keratitis.

              Lead Product(s): Polyhexanide

              Therapeutic Area: Infections and Infectious Diseases Product Name: Akantior

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable May 31, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              SIFI

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Italy
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Sifi Announces License Agreement with Avanzanite Bioscience for Akantior®

              Details:

              AKANTIOR® (polihexanide) is an investigational anti-amoebic polymer that has been granted Orphan Drug Designation by both the European Medicines Agency ("EMA") and Food and Drug Administration ("FDA") for AK.

              Lead Product(s): Polyhexanide

              Therapeutic Area: Infections and Infectious Diseases Product Name: Akantior

              Highest Development Status: Preclinical Product Type: Small molecule

              Recipient: Avanzanite Bioscience

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement January 10, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              SIFI

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Italy
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              SIFI Reports Detailed Positive Results and New Data from the Completed Phase 3 Trial of AKANTIOR® in Patients with Acanthamoeba Keratitis presented at the American Academy...

              Details:

              87% of patients receiving AKANTIOR® in the Phase 3 Trial were medically cured within a median duration of 4 months compared to 55% with the treatment protocols used in real-world clinical practice today.

              Lead Product(s): Polyhexanide

              Therapeutic Area: Infections and Infectious Diseases Product Name: Akantior

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable October 13, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              SIFI

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Italy
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Alimera Announces Approval and Pricing Granted for ILUVIEN for Uveitis in Italy

              Details:

              ILUVIEN (fluocinolone acetonide intravitreal implant) 0.19 mg sustained release intravitreal implant, injected into back of eye,is designed to release sub-microgram levels of fluocinolone acetonide, a corticosteroid, for 36 months, to reduce recurrence of disease.

              Lead Product(s): Fluocinolone Acetonide

              Therapeutic Area: Ophthalmology Product Name: Iluvien

              Highest Development Status: Phase IV Product Type: Small molecule

              Recipient: Alimera Sciences

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable July 08, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              SIFI

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Italy
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Sifi Announces EMA Validation Of Its Marketing Authorisation Application For Akantior For The Treatment Of Acanthamoeba Keratitis And The Opening Of An Early Access Program

              Details:

              AKANTIOR® (polihexanide) stands to become first approved drug for the treatment of acanthamoeba keratitis in the world. It is an anti-amoebic polymer that acts on both the trophozoites and cysts of the protozoan Acanthamoeba.

              Lead Product(s): Polyhexanide

              Therapeutic Area: Infections and Infectious Diseases Product Name: Akantior

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: Durbin

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable June 07, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              SIFI

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Italy
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Sifi Receives Favorable Feedback From the US FDA on Akantior® for the Treatment of Acanthamoeba Keratitis

              Details:

              AKANTIOR (polihexanide) stands to become the first approved drug for the treatment of acanthamoeba keratitis in the world. Polihexanide, a New Chemical Entity (NCE), is an anti-amoebic polymer that acts on both the trophozoites and cysts of the protozoan Acanthamoeba.

              Lead Product(s): Polyhexanide

              Therapeutic Area: Infections and Infectious Diseases Product Name: Akantior

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable May 16, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              SIFI

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Italy
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              SIFI Initiates Patient Enrollment in Phase II Trial evaluating Pro-Ocular in Dry Eye Disease

              Details:

              ProGIFT is a multicenter, randomized, double-masked, placebo-controlled Phase II clinical trial comparing different concentrations of Pro-ocular (1% and 0.5%) versus placebo.

              Lead Product(s): Progesterone

              Therapeutic Area: Ophthalmology Product Name: Pro-ocular

              Highest Development Status: Phase II/ Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 27, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              SIFI

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Italy
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              SIFI Completes Enrollment of the Phase III Study of Polihexanide 0.08% for the Treatment of Acanthamoeba Keratitis

              Details:

              SIFI is conducting a multi-center randomized, double-masked, and active-controlled Phase III trial designed to evaluate the efficacy, safety, and local tolerability of polihexanide 0.08% compared to a combination of polihexanide 0.02% and 0.1% propamidine.

              Lead Product(s): Polyhexanide

              Therapeutic Area: Ophthalmology Product Name: PH043

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable November 19, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Farmhispania Group, a leading European CDMO in HPAPI Technologies & High Potency Fermentation.
              One Pharma aims to be one of the leading generic companies in Europe.
              Post Enquiry
              POST ENQUIRY